glp 1 drugs and parkinson's disease GLP-1 does not slow progression in phase 3 study The glucagon-like peptide 1 (GLP)

GLP-1 and GIP control blood glucose levels by stimulating insulin secretion by pancreatic -cells while inhibiting glucagon secretion, increasing pancreatic -cell proliferation, and decreasing their apoptosis [3,4,5,6,7,8]

doi: 10.1007/s13300-018-0377-5

The growing use of GLP-1 drugs in clinical practice makes these findings particularly significant

Low blood sugar can occur in diabetic patients if medication dosages are not adjusted

your provider will follow the appropriate clinical protocols to start you at the lowest dose and move up as needed

Lastly, the findings on the association between GLP-1 RA use and lower rates of new-onset blindness were based on administrative coding of visual impairment, not eye examination data